Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more
Bioventix PLC (51B) - Net Assets
Latest net assets as of June 2025: €11.55 Million EUR
Based on the latest financial reports, Bioventix PLC (51B) has net assets worth €11.55 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.86 Million) and total liabilities (€1.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €11.55 Million |
| % of Total Assets | 89.8% |
| Annual Growth Rate | 1.64% |
| 5-Year Change | -2.27% |
| 10-Year Change | N/A |
| Growth Volatility | 6.55 |
Bioventix PLC - Net Assets Trend (2017–2025)
This chart illustrates how Bioventix PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bioventix PLC (2017–2025)
The table below shows the annual net assets of Bioventix PLC from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €11.55 Million | -3.76% |
| 2024-06-30 | €12.00 Million | -0.51% |
| 2023-06-30 | €12.06 Million | +2.05% |
| 2022-06-30 | €11.82 Million | +0.01% |
| 2021-06-30 | €11.82 Million | -5.60% |
| 2020-06-30 | €12.52 Million | +15.65% |
| 2019-06-30 | €10.83 Million | -1.68% |
| 2018-06-30 | €11.01 Million | +8.54% |
| 2017-06-30 | €10.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bioventix PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €9.75 Million | 84.39% |
| Other Components | €1.80 Million | 15.61% |
| Total Equity | €11.55 Million | 100.00% |
Bioventix PLC Competitors by Market Cap
The table below lists competitors of Bioventix PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Indomobil Sukses Internasional
JK:IMAS
|
$67.74 Million |
|
Rane (Madras) Limited
NSE:RML
|
$67.77 Million |
|
TTEC Holdings Inc
NASDAQ:TTEC
|
$67.78 Million |
|
289930
KQ:289930
|
$67.81 Million |
|
Premier Marketing Public Company Limited
BK:PM
|
$67.72 Million |
|
Baazar Style Retail Limited
NSE:STYLEBAAZA
|
$67.69 Million |
|
Robot Consulting Co., Ltd. ADS
NASDAQ:LAWR
|
$67.69 Million |
|
Berjaya Corporation Berhad
PINK:BRYAF
|
$67.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioventix PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,002,658 to 11,551,717, a change of -450,941 (-3.8%).
- Net income of 7,584,442 contributed positively to equity growth.
- Dividend payments of 8,194,860 reduced retained earnings.
- New share issuances of 70,254 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €7.58 Million | +65.66% |
| Dividends Paid | €8.19 Million | -70.94% |
| Share Issuances | €70.25K | +0.61% |
| Other Changes | €89.22K | +0.77% |
| Total Change | €- | -3.76% |
Book Value vs Market Value Analysis
This analysis compares Bioventix PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.05x to 7.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-06-30 | €1.97 | €15.90 | x |
| 2018-06-30 | €2.14 | €15.90 | x |
| 2019-06-30 | €2.11 | €15.90 | x |
| 2020-06-30 | €2.40 | €15.90 | x |
| 2021-06-30 | €2.27 | €15.90 | x |
| 2022-06-30 | €2.27 | €15.90 | x |
| 2023-06-30 | €2.31 | €15.90 | x |
| 2024-06-30 | €2.30 | €15.90 | x |
| 2025-06-30 | €2.21 | €15.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioventix PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 65.66%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 57.83%
- • Asset Turnover: 1.02x
- • Equity Multiplier: 1.11x
- Recent ROE (65.66%) is above the historical average (59.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 48.52% | 67.93% | 0.70x | 1.02x | €3.91 Million |
| 2018 | 51.43% | 64.71% | 0.74x | 1.08x | €4.56 Million |
| 2019 | 54.14% | 63.10% | 0.80x | 1.07x | €4.78 Million |
| 2020 | 57.53% | 69.84% | 0.78x | 1.06x | €5.95 Million |
| 2021 | 56.95% | 61.58% | 0.85x | 1.09x | €5.55 Million |
| 2022 | 64.92% | 65.48% | 0.89x | 1.11x | €6.49 Million |
| 2023 | 69.40% | 65.33% | 0.96x | 1.10x | €7.17 Million |
| 2024 | 67.46% | 59.51% | 0.99x | 1.14x | €6.90 Million |
| 2025 | 65.66% | 57.83% | 1.02x | 1.11x | €6.43 Million |
Industry Comparison
This section compares Bioventix PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioventix PLC (51B) | €11.55 Million | 48.52% | 0.11x | $67.73 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |